Fully automated thrombin generation assays: current characteristics, advances, and clinical relevance

The thrombin generation assay (TGA) is a diagnostic tool that enables a global assessment of hemostasis. In recent years, technical advances have been made to achieve full automation of these assays, with the aim of ensuring standardization and consistency across studies. Currently, two fully automated devices are available: ST-Genesia® (Diagnostica Stago, Asnièressur- Seine, France) and Ceveron® alpha TGA (Technoclone, Vienna, Austria). This is a highly versatile tool that has demons-trated clinical applicability both in the field of bleeding disorders – by assessing patients’ bleeding phenotypes and monitoring their hemostatic treatment – and in thrombotic disorders, as it can identify thrombotic risk profiles not only for venous thrombosis but also for cardiovascular risk and cancer-associated thrombosis. Its role is also being investigated in the monitoring of anticoagulant therapy and the hemostatic status of patients with liver cirrhosis.